ANTISENSE COMPOUNDS TARGETING LEUCINE-RICH REPEAT KINASE 2 (LRRK2) FOR THE TREATMENT OF PARKINSONS DISEASE - Patent 3724335

(19)

(11)

EP 3 724 335 A1

(12)

(43)	Date of publication:
	21.10.2020 Bulletin 2020/43

(21)	Application number: 18830581.7

(22)	Date of filing: 10.12.2018

(51)

International Patent Classification (IPC):

C12N 15/113^(2010.01)

(86)	International application number:
	PCT/US2018/064693

(87)	International publication number:
	WO 2019/118325 (20.06.2019 Gazette 2019/25)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

11.12.2017 US 201715837926

(71)	Applicants:
	Rosalind Franklin University of Medicine and Science North Chicago, IL 60064 (US) The McLean Hospital Corporation Belmont, MA 02487 (US)

(72)	Inventors:
	HASTINGS, Michelle, L. Chicago, IL 60064 (US) ISACSON, Ole Belmont, MA 02487 (US) KORECKA-ROET, Joanna, A. Belmont, MA 02487 (US)

(74)	Representative: Müller-Boré & Partner Patentanwälte PartG mbB
	Friedenheimer Brücke 21 80639 München 80639 München (DE)

(54)	ANTISENSE COMPOUNDS TARGETING LEUCINE-RICH REPEAT KINASE 2 (LRRK2) FOR THE TREATMENT OF PARKINSONS DISEASE